A new trading day began on Monday, with Iterum Therapeutics Plc (NASDAQ: ITRM) stock price down -3.46% from the previous day of trading, before settling in for the closing price of $0.37. ITRM’s price has ranged from $0.36 to $2.10 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 58.85%. Meanwhile, its annual earnings per share averaged 25.84%. With a float of $52.37 million, this company’s outstanding shares have now reached $52.79 million.
Iterum Therapeutics Plc (ITRM) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Iterum Therapeutics Plc is 0.79%, while institutional ownership is 2.52%. The most recent insider transaction that took place on Nov 18 ’25, was worth 2,191. In this transaction Director of this company bought 6,000 shares at a rate of $0.37, taking the stock ownership to the 241,001 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Director bought 15,000 for $0.72, making the entire transaction worth $10,854. This insider now owns 235,001 shares in total.
Iterum Therapeutics Plc (ITRM) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.12 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.77% during the next five years compared to 58.85% growth over the previous five years of trading.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Here are Iterum Therapeutics Plc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 48.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Compared to the last year’s volume of 0.69 million, its volume of 0.6 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 5.13%.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 0.58%, which indicates a significant decrease from 1.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0374 in the past 14 days, which was lower than the 0.0489 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5368, while its 200-day Moving Average is $0.8461. Nevertheless, the first resistance level for the watch stands at $0.3663 in the near term. At $0.3755, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3816. If the price goes on to break the first support level at $0.3510, it is likely to go to the next support level at $0.3449. Now, if the price goes above the second support level, the third support stands at $0.3357.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
With a market capitalization of 18.86 million, the company has a total of 52,788K Shares Outstanding. Currently, annual sales are 0 K while annual income is -24,770 K. The company’s previous quarter sales were 390 K while its latest quarter income was -8,980 K.
